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The last decade has witnessed tremendous progress in the understanding of the mineralocorticoid receptor
(MR), its molecular mechanism of action, and its implications for physiology and pathophysiology. After the
initial cloning of MR, and identification of its gene structure and promoters, it now appears as a major actor
in protein-protein interaction networks.The role of transcriptional coregulators and the determinants of
mineralocorticoid selectivity have been elucidated.Targeted oncogenesis and transgenic mouse models have
identified unexpected sites of MR expression and novel roles for MR in non-epithelial tissues.These
experimental approaches have contributed to the generation of new cell lines for the characterization of
aldosterone signaling pathways, and have also facilitated a better understanding of MR physiology in the
heart, vasculature, brain and adipose tissues.This review describes the structure, molecular mechanism of
action and transcriptional regulation mediated by MR, emphasizing the most recent developments at the
cellular and molecular level. Finally, through insights obtained from mouse models and human disease, its
role in physiology and pathophysiology will be reviewed. Future investigations of MR biology should lead to
new therapeutic strategies, modulating cell-specific actions in the management of cardiovascular disease,
neuroprotection, mineralocorticoid resistance, and metabolic disorders.
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A brief history
In the late 1960s, evidence for the presence of specific
receptors mediating corticosteroid action in the toad
bladder was initially proposed by the group of Edelman
[Porter and Edelman, 1964]. Subsequently, Type I and
Type II corticosteroid receptors were described and
identified as mineralocorticoid (MR) and glucocorticoid
receptors (GR) [Marver et al., 1974]. MR was
characterized as a high affinity (Kd~1 nM), low capacity
(20-50 fmol/mg protein) receptor and demonstrated to be
a major regulator of sodium reabsorption in the kidney
[Funder et al., 1972]. Fifteen years later, the human MR
(hMR) cDNA was cloned by the Evans laboratory by
screening a human kidney cDNA library at low stringency
with a probe encompassing the DNA binding domain of
the GR [Arriza et al., 1987]. MR was subsequently cloned
and characterized in many species including Xenopus,
fish (zebra fish, teleost fish [Greenwood et al., 2003],
rainbow trout [Sturm et al., 2005]), bird [Hodgson et al.,
2007; Porter et al., 2007] and mammals (mouse, rat [Patel
et al., 1989], mole, pig, cow, monkey [Patel et al., 2000;
Pryce et al., 2005]). In the late 1990s came the
identification of multiple transcription coregulators that
mediate MR transcriptional potency at aldosterone-target
genes, as reviewed by [O'Malley, 2007]. MR is now
recognized as a crucial transcription factor involved in
many physiological processes and pathological disorders.
Structure
Structure of the gene
The gene NR3C2 encoding the hMR is located on
chromosome 4 in the q31.1 region and spans
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al., 1995]. As illustrated in Figure 1, the gene is composed
of ten exons; the first two exons, 1α and 1β, are
untranslated, and the following eight exons encode the
entire MR protein of 984 amino acids (aa).The rat MR
gene is located on chromosome 19q11 and differs slightly
in having three untranslated exons (1α, 1β and 1γ) and
encoding a 981 aa protein [Kwak et al., 1993]; a similar
genomic structure is found for mouse MR gene, which
encodes a 978 aa protein. In addition, it now appears that
the MR gene does not encode only one protein, but gives
rise to multiple mRNA isoforms and protein variants
[Pascual-Le Tallec and Lombes, 2005], thus allowing
combinatorial patterns of receptor expression potentially
responsible for distinct cellular and physiological
responses in a tissue-specific manner.
Structure of the protein
Like all members of the nuclear receptor superfamily, MR
has three major functional domains; a N-terminal domain
(NTD), followed by a central DNA-binding domain (DBD),
and a hinge region linking them to a C-terminal
ligand-binding domain (LBD). Exon 2 encodes most of
the NTD, small exons 3 and 4 for each of the two zinc
fingers of the DBD, and the last five exons for the LBD
(Figure 1).
The MR NTD is the longest among all the steroid
receptors (SR), (602 aa).The NTD is highly variable
among SR, showing less than 15% identity, but for a given
receptor, highly conserved between species (more than
50% homology), strongly suggesting a crucial functional
importance.The NTD possesses several functional
domains responsible for ligand-independent
transactivation or transrepression, as shown schematically
in Figure 1.Two distinct activation function 1 domains
(AF1), referred to as AF1a (residues 1-167) and AF1b
(residues 445-602), have been demonstrated in both rat
[Fuse et al., 2000] and human MR [Pascual-Le Tallec et
al., 2003]. A central inhibitory domain (residues 163-437)
has also been characterized and seems to be sufficient
to attenuate the overall transactivation strength of the
NTD fused either to AF-1a or AF-1b [Pascual-Le Tallec
et al., 2003].These different domains of the NTD recruit
various coregulators responsible for modulating the
transcriptional activity of MR in a highly selective manner
compared with other SR, and are now considered to be
important determinants of mineralocorticoid selectivity
[Pascual-Le Tallec and Lombes, 2005].
The DBD has the ability to recognize specific target DNA
sequences or hormone response elements (HRE).The
MR DBD is 94% identical with that of GR, and more than
90% compared with the progesterone receptor (PR) and
the androgen receptor (AR).The MR DBD is a 66 aa
domain encoded by exons 3 and 4: by analogy with the
crystal structure obtained of the GR DBD, it contains two
perpendicular α helices, structurally coordinated by a zinc
ion that interacts with four cysteine residues and is thus
responsible for the zinc finger’s structure.The first zinc
finger contains the “P box” (defined by the three residues
Gly621Ser-Val625) responsible for tight binding to the minor
groove of the DNA double helix.The second zinc finger
facilitates receptor dimerization through the so-called “D
box” (Ala640GlyArgAsnAsp645), located in the N-terminal
part of the DBD. In this context, it is interesting to note
that MR is able to heterodimerize with other members of
the SR subgroup, most notably GR and AR [Liu et al.,
1995], consistent with the possibility that
heterodimerization might play a role in some physiological
responses at the level of transcriptional regulation.
The MR LBD is a complex and multifunctional domain
that spans 251 aa. It is relatively conserved among SR
(~55% homology) and highly conserved across species
(80-97% homology), and allows selective hormone
binding, thus transducing endocrine messages into
specific transcriptional responses.The MR LBD crystal
structure has recently been solved, thus confirming the
remarkable similarity in structure among all SR [Bledsoe
et al., 2005; Fagart et al., 2005; Li et al., 2005]. Basically,
the MR LBD consists of 11 α helices and four small
antiparallel β strands that fold into a three layer helical
sandwich. Solving the crystal structure allowed
identification of the crucial amino acid residues interacting
with the functional group of steroid ligands. For instance,
Gln776 of helix H3 and Arg817 at the end of helix 5 directly
contact the 3-ketone group of aldosterone, and Asn770
of helix H3 stabilizes aldosterone 18-hydroxyl group.
Other residues in helices 6 and 7, as well as Thr945 on
helix 10, also directly contact the steroid ligand. A single
residue at position 848 in helix H7 switches hormone
specificity between MR and GR [Li et al., 2005], and
amino acids 820-844 (which are not part of the ligand
binding pocket) are also critical for aldosterone binding
and ligand binding selectivity [Rogerson et al., 2007].The
role of Met852 in accommodating the C7 substituents of
antimineralocorticoid spirolactones has very recently been
described [Huyet et al., 2007]. Finally, on the basis of the
high similarity between the LBD of MR and GR, and
considering the evolutionary tree of this receptor
subgroup, it has been proposed that MR was closer to
the primordial ancestral corticosteroid receptor [Hu and
Funder, 2006], which has been proposed as having high
affinity for aldosterone, well before the hormone appeared
[Bridgham et al., 2006]. In this context, it is also interesting
to note that the Ser949 in human MR is deleted in almost
all GR and that the His950 in human MR, conserved in
MR in Old World monkeys, is a glutamine in all teleost
and land vertebrate MR and may thus represent a
breaking point during evolution [Baker et al., 2007].
The MR LBD possesses a ligand-dependent AF-2
constituted by the helices H3, H4, H5 and H12. Upon
ligand binding, a rearrangement of the LBD occurs: H12
closes over the ligand pocket which, in combination with
the bending of helices H3, H5 and H11, forms a
hydrophobic cleft on the surface of the LBD.This groove
serves as a docking surface for transcriptional
coactivators possessing a NR box defined by the LXXLL
motif, an interaction essential for activation of MR
transcriptional activity. Given the high level of homology
between their LBDs, it is not surprising that GR and MR
recruit almost identical coactivators through their AF2
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Review The mineralocorticoid receptorFigure 1.  Schematic representation of human MR structure. MR gene, mRNA, protein, functional domains and associated posttranslational
modifications are depicted.The hMR gene is composed of ten exons, including two untranslated first exons (1α and 1β).The AUG translational initiation
start codon is located 2 bp after the beginning of exon 2, while the stop codon is located in exon 9. Multiple mRNA isoforms generated by alternative
transcription or splicing events are translated into various protein variants, including those generated by utilization of alternative translation initiation
sites (not shown).The receptor is comprised of distinct functional domains (activation function AF-1a, AF-1b and AF-2) and nuclear localization signals
(NLS0, NLS1 and NSL2), as well as one nuclear export signal (NES).The positioning of amino acids targeted for phosphorylation, sumoylation,
acetylation and ubiquitylation is indicated for the human MR sequence.
domains. A recent study, using an isolated MR LBD as
bait to screen interaction with a LXXLL peptide library
showed that MR interacts with a restricted number of
coactivator peptides including SRC-1, ASC2, PGC-1α
and PGC-1β [Hultman et al., 2005].
Although the relative contributions of AF1a, AF1b and
the AF2 to MR transcriptional activity appears to be highly
dependent on cellular and promoter contexts, the NTD
appears to account for ~40-50% of total transactivation
and represents a key determinant of MR specificity
[Pascual-Le Tallec and Lombes, 2005].
As noted above, MR is expressed as at least two different
proteins, MRA and MRB [Pascual-Le Tallec et al., 2004],
resulting from strong Kozak sequences initiating
alternative translation.These variants display distinct
transactivation capacities in vitro; it remains to be
established whether they are differentially expressed in
vivo, and the extent to which they contribute to fine-tuning
of MR transcriptional activity and the differential patterns
of gene expression in different cellular contexts, as
previously described for GR [Lu and Cidlowski, 2005].
Interactions
In its non-liganded state, MR interacts with a large variety
of proteins, most notably in the cytoplasmic compartment,
thus forming part of a hetero-oligomer [Rafestin-Oblin et
al., 1989]. MR contacts chaperone proteins such as the
heat shock protein hsp90 [Binart et al., 1995], and
indirectly interacts with hsp70, the p23 and p48 proteins
and the FKBP-59 immunophilins or CYP40 cyclophillin
[Bruner et al., 1997; Pratt and Toft, 1997].These
chaperones play a pivotal role in maintaining MR in an
appropriate conformation for ligand binding. Besides the
chaperone proteins, the MR also interacts with actin
[Jalaguier et al., 1996], which may thus play a role in the
ligand-dependent nuclear translocation. Upon hormone
binding, the MR dissociates from chaperone proteins,
undergoes nuclear translocation and interacts with
numerous molecular partners in a coordinate and
sequential manner to ensure appropriate transcriptional
regulation. For over a decade, yeast two-hybrid screening,
GST pulldown and coimmunoprecipitation assays have
been used to identify various MR-interacting nuclear
proteins.
From a functional point of view, the most important are
the transcriptional coregulators acting either as
coactivators or corepressors of MR transactivation. Since
the initial description of coactivators in the mid 1990s,
our knowledge of the complexity of transcriptional
regulation has considerably increased. SR are now
considered as platforms recruiting in an ordered and
cyclical manner different coregulators [Metivier et al.,
2003], which exhibit various enzymatic activities to play
the role of transcriptional master switches [O'Malley,
2007].The first member of the large coactivator family
identified was steroid receptor coactivator-1 (SRC-1)
[Onate et al., 1995], postulated to initiate transcription by
recruiting a series of proteins involved in chromatin
remodeling, histone acetylation and methylation [Freiman
and Tjian, 2003; Rosenfeld et al., 2006]. Since then, a
dozen coregulators have been demonstrated to interact
with MR and modulate its activity (for an exhaustive
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2005]). As summarized and referenced in Table 1, the
most important coactivators for MR transactivation
appeared to be the histone acetylase CBP/p300; the
helicase RHA; the transcriptional coactivators SRC-1,
SRC-1e, and PGC-1; and finally, the Pol II elongation
factor ELL, that constitutes the first example of a selective
transcriptional coregulator of MR [Pascual-Le Tallec et
al., 2005]. Corepressors able to bind MR and repress its
transcriptional function include the widely repressive
SMRT and NCoR; the apoptosis regulator DAXX; and
the specific SUMO-ligase PIAS proteins. Of interest,
sumoylation now emerges as an important
posttranslational modification for many nuclear receptors
and coregulators. SUMO-E3 ligase PIAS proteins repress
MR, potentially in collaboration with DAXX protein [Lin et
al., 2006]; it has recently been shown, however, that the
SUMO-E2 activating enzyme Ubc9 interacts with the MR
NTD/DBD (1-670 aa) to potentiate aldosterone-dependent
MR transactivation [Yokota et al., 2007], further increasing
the complexity of sumoylation-mediated regulation.The
MR interaction network per se appears not to determine
functional MR activity; rather, the coordination and
sequential interaction of molecular partners, directly or
indirectly with MR, controls activation and function of
cooperative transcriptional complexes, probably in a cell-
and promoter-dependent manner. It should be mentioned
that MR also heterodimerizes with other SR, notably GR
and AR [Liu et al., 1995; Savory et al., 2001], thus
providing additional support for MR functional diversity
of action.
MR expression
Until the late 1970s, MR expression measured by binding
assays was considered restricted to polarized tight
epithelia, which show aldosterone-dependent
transepithelial sodium transport [Marver et al., 1974]. MR
expression was located by immunohistochemistry in the
kidney, most notably in the distal convoluted tubules and
cortical collecting ducts [Krozowski et al., 1989; Lombes
et al., 1990]. MR seems also to be expressed at the
messenger and the protein levels in glomeruli, especially
in mesangial cells [Miyata et al., 2005; Nishiyama et al.,
2005] and podocytes [Shibata et al., 2007], where
aldosterone has been reported to modulate podocyte
function, possibly through the induction of oxidative stress
and of the serum and glucocorticoid-regulated kinase 1
(SGK1). MR expression was also detected, by specific
binding of [
3H]-aldosterone, in the distal colon of rat
[Pressley and Funder, 1975], human [Lombes et al., 1984]
and chick [Rafestin-Oblin et al., 1989].The lung may
represent another aldosterone target tissue, in that MR
binding sites were demonstrated in airway epithelia from
bronchiole to trachea [Krozowski and Funder, 1981]. MR
expression (transcript and/or protein) was clearly revealed
in the salivary [Funder et al., 1972] and sweat glands
[Kenouch et al., 1994], in the liver [Duval and Funder,
1974] and in the inner ear [Furuta et al., 1994; Pitovski
et al., 1993;Teixeira et al., 2006]. Importantly, epithelial
expression of MR was always associated with expression
of the 11β-hydroxysteroid dehydrogenase 2 (11β-HSD2),
the enzyme that allows aldosterone to selectively activate
MR, by converting glucocorticoid hormones to their
11-keto analogs, unable to bind MR [Edwards et al., 1988;
Funder et al., 1988].
Subsequently, MR expression was detected in
non-epithelial tissues in which the expression of
11β-HSD2 was absent or extremely low. For instance,
specific binding sites for aldosterone were identified in
mononuclear leucocytes [Armanini et al., 1985] and in
the heart [Barnett and Pritchett, 1988; Pearce and Funder,
1987] and MR transcripts were detected in specific
structures of the hippocampus (dentate gyrus and CA1,
2, and 3 nuclei) and in the hypothalamus [Han et al.,
2005; Herman et al., 1989;Van Eekelen et al., 1988]. In
1992, MR was localized at the cellular level by
immunohistochemistry in cardiomyocytes, endothelial
cells and large vessels [Lombes et al., 1992]. Some years
later, MR expression was confirmed, at the messenger
and protein level in the skin, not restricted to sweat and
sebaceous glands, but also in keratinocytes constituting
the stratified epithelium [Kenouch et al., 1994]. Recent
studies have shown MR to be expressed at the transcript
and protein level in adipose tissues, both in white [Caprio
et al., 2007; Fu et al., 2005; Rondinone et al., 1993] and
brown adipocytes [Penfornis et al., 2000;Viengchareun
et al., 2001; Zennaro et al., 1998].This is of particular
interest considering the functional interaction between
MR and PGC-1 [Hultman et al., 2005] and the central role
of this coactivator for brown adipocyte differentiation [Lin
et al., 2005]. Of note, MR is also expressed at the protein
level in ocular tissues, such as retina [Mirshahi et al.,
1997] and iris-ciliary body [Schwartz and Wysocki, 1997],
in placenta [Hirasawa et al., 2000], and at the messenger
level in uterus, ovaries and testis [Le Menuet et al., 2000],
with no clear roles reported to date.
This widespread expression of MR suggests novel
functions for this receptor in these target tissues. It also
raises questions regarding the role played by
glucocorticoid hormones (cortisol or corticosterone) in
MR activation, considering the absence of 11β-HSD2 in
non-epithelial tissues, except in certain brain areas such
as the nucleus of the solitary tract, as recently reported
[Geerling et al., 2006; Naray-Fejes-Toth and Fejes-Toth,
2007].
MR is now considered an ubiquitous transcription factor,
and real-time PCR quantification of MR and GR
transcripts reveals interesting anatomical expression
patterns [Bookout et al., 2006]. MR and GR expression
are equivalent and high in the gastrointestinal system,
and moderate in the endocrine, reproductive, metabolic
and cardiovascular systems. MR expression is higher
than that of GR in the central nervous system (CNS) and
the structural system (skeleton), whereas GR expression
is, as expected, more pronounced than that of MR in the
immune system. According to the classification based on
hierarchical clustering of gene expression, MR seems to
belong to the same cluster as LXRβ and RXRβ, the
expression of which is most abundant in the CNS and is
crucial to the global basal metabolism, linked to circadian
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Their names, functions and putative interacting domains are shown, together with the corresponding references.
clocks, metabolism and cardiovascular control [Bookout
et al., 2006].Thus, distinct MR and GR expression
patterns strongly support that MR and GR differentially
affect transcriptional programs governing distinct
physiological processes and pathophysiological disorders.
Regulation of MR expression
A key step in the mineralocorticoid response is the
regulation of the MR expression level. Indeed, in
non-epithelial tissues, such as the hippocampus, MR
exerts its action in balance with the GR [de Kloet, 2003].
In the brain, some compounds, such as serotonin [Lai et
al., 2003] and progesterone [Castren et al., 1995], have
been reported to modulate MR mRNA expression. In
other tissues, MR expression levels positively correlate
with the severity of heart [Yoshida et al., 2005] and kidney
failure [Quinkler et al., 2005]. Of major interest, a recent
report showed that lowering renal expression of MR by
a RNA interference strategy in cold-induced hypertensive
rats both prevented the progression of hypertension and
attenuated renal damage [Wang et al., 2006],
emphasizing the potential importance of regulation of MR
expression.The hMR gene has two 5’ untranslated exons
(1α and 1β) alternatively spliced onto exon 2.Their
5’-flanking regions were identified as functional promoters,
referred to as P1 and P2, respectively, and these were
studied in transient transfection assays [Zennaro et al.,
1996].The basal transcriptional activity of the P1
(proximal) promoter is stronger than that of the P2 (distal)
promoter. In vitro, while both promoters are stimulated
by glucocorticoids, only P2 is activated by aldosterone.
Transgenic mouse models were established by targeted
oncogenesis with each promoter fused to the simian virus
40 large T antigen as a reporter gene, providing a unique
opportunity to examine tissue-specific utilization of these
promoters in vivo [Le Menuet et al., 2000] and to establish
novel mineralocorticoid-sensitive cell lines [Le Menuet et
al., 2004].The P1 promoter was shown to be active in
vivo in all MR-expressing tissues, whereas the P2
promoter activity was much lower and appeared to be
restricted to development, questioning the role of the P2
promoter and the molecular events and transcription
factors involved in regulation of the MR promoter in vivo.
Cellular mechanisms and cellular
biology
Subcellular distribution
In the absence of ligand, MR is located mainly in the
cytoplasm [Binart et al., 1991; Lombes et al., 1994a],
associated with chaperone proteins. Upon ligand binding
and dissociation of receptor-associated proteins, activated
MR translocates into the nuclear compartment, in
response to nuclear localization signals (NLS) present in
the receptor protein sequence.Three functional NLS have
been described so far [Walther et al., 2005] and are
depicted in Figure 1.The first one, (NLS0), is located at
the end of the NTD, between amino acids 590 and 602.
It possesses five serine and one threonine residues that
play a crucial role in the MR nuclear import dependent
upon Ser601 phosphorylation.The NLS2 is located in the
receptor LBD, as a sequence without any basic amino
acids, a feature of NLS sequences in other SR. Nuclear
translocation mediated by NLS2 seems to depend on the
nature of the ligand; only MR agonists induce rapid
translocation of the receptor, with antagonists less
effective [Lombes et al., 1994a].The third sequence,
(NLS1), is located in the C-terminal part of the DBD; NLS1
acts cooperatively with NLS0 and NLS2 to facilitate
nuclear translocation of the unbound MR [Walther et al.,
2005]. In addition, a nuclear export signal (NES) is located
between the two zinc fingers of the DBD near the NLS1
[Black et al., 2001]. Altogether, these data indicate that
MR is a receptor, the distribution of which is an active
process under the control of functional NLS.
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for corticosteroids might mediate their rapid effects on
cortical collecting duct cells [Le Moellic et al., 2004] and
on CA1 pyramidal neurons [Karst et al., 2005] through a
nongenomic signaling pathway, evidence for a
membrane-bound MR is lacking.
Promoter binding and transcriptional activation
Upon ligand binding, MR moves into the nucleus acting
as a transcription factor by binding to specific HRE
present in target genes potentially located up to 10 kb
upstream or downstream from transcriptional start sites,
as recently described for GR and GREs [So et al., 2007].
This study reported that GRE sequences vary extensively
around a consensus, but are strikingly conserved for a
given site across species, raising the possibility of distinct
sets of MREs versus GREs for MR target genes. MR,
when bound to response elements, recruits chromatin
remodeling complexes to release the nucleosome
structure, and components of the transcriptional
machinery to activate Pol II transcription. A complete and
sequential picture of the transcriptional events remains
to be clearly established for MR.
Posttranslational modifications
Even though phosphorylation of SR has been shown to
play a major role in modulating their intrinsic function, MR
phosphorylation has received little attention so far, despite
an early report describing MR as a phosphoprotein
[Alnemri et al., 1991]. Several tyrosine, serine and
threonine residues are present throughout the MR protein
(Figure 1). A tyrosine to cysteine substitution (Y73C), at
a potential phosphorylation site, was identified in the NTD
of the Brown Norway rat as opposed to Fischer 344 rat,
and was associated with increased MR transactivation
and unexpectedly, partial activation by progesterone
[Marissal-Arvy et al., 2004].This tyrosine phosphorylation
site is also present in hMR and could thus be implicated
in potential pathophysiological dysregulation.
Phosphorylation sites at Thr735 and Ser737 were recently
identified in the hMR LBD by proteomic analysis
[Hirschberg et al., 2004], and may thus participate in LBD
conformational change. In addition, as mentioned above,
mutations in the serine/threonine-rich sequence in the
MR NLS0, most notably Ser601, have highlighted their
role in receptor subcellular shuttling [Walther et al., 2005].
MR is phosphorylated within minutes after aldosterone
exposure on serine and threonine residues by the protein
kinase C α, leading to subsequent ionic transport [Le
Moellic et al., 2004], and providing strong evidence for
cross-talk between early (<30 min) non-genomic and late
(>2h) genomic effects of MR and aldosterone (for detailed
review see [Funder, 2005]).
Recently, sumoylation has emerged as an extremely
important posttranslational modification for regulation of
transcription factors, most notably members of the nuclear
receptor superfamily [Seeler and Dejean, 2003].
Sumoylation entails a covalent link with small
ubiquitin-related modifier (SUMO). MR possesses several
sumoylation consensus motifs defined by the peptide
sequence site ΨKXE, where Ψ is an aliphatic residue, K
the target lysine for sumoylation and X any residue. Four
SUMO sites have been identified in the NTD at positions
K89, K399, K428, K494 and one in the LBD at position K953
[Pascual-Le Tallec et al., 2003] (see Figure 1).The
consensus sites, also named synergy control motif
[Iniguez-Lluhi and Pearce, 2000], are highly conserved
throughout evolution, supporting an important functional
role for sumoylation. Indeed, sumoylation is now
considered a general repressive mechanism for many
transcription factor functions. MR-mediated transcription
is repressed by sumoylation to an extent dependent on
the nature of the response element bound, in that it may
impair protein-protein interactions with the transcriptional
initiation complex. Acetylation mediated by the p300 and
p/CAF proteins has been reported for other SR.The
KXKK/RXKK acetylation motif is a perfect match with the
MR NLS1, most notably the K677, suggesting that MR
acetylation might affect not only ligand-dependent
nucleo-cytoplasmic shuttling, but also protein-protein
interaction and subsequent transcriptional regulation.The
exact impact of acetylation on MR function, and the
relative contribution of CBP/p300 and HDAC warrant
further investigation.
Very recently, ubiquitylation (or ubiquitination), another
posttranslational modification of MR, has been reported.
MR can be poly-ubiquitylated and targeted to the
proteasome, a mechanism which seems to be essential
for the regulation of MR-mediated transcriptional
activation [Tirard et al., 2007].
Target genes and their biological
functions
Epithelial tissues
In classical polarized epithelial tissues (i.e., kidney, colon),
MR regulates salt balance and water homeostasis by
directly stimulating expression of specific ionic
transporters active at the cellular membrane: the
amiloride-sensitive Epithelial Na Channel (ENaC), located
at the apical membrane [Canessa et al., 1994; Rossier
et al., 2002], and the basolateral Na
+,K
+-ATPase pump
[Horisberger et al., 1991; Jorgensen, 1986].These
transporters are responsible for unidirectional
transepithelial sodium transport from the lumen to the
interstitium. Figure 2 illustrates a schematized model of
aldosterone action in an epithelial renal cell and Table 2
summarizes early aldosterone-induced genes, identified
in epithelial tissues.They include the ENaC subunits
[Bens et al., 1999; Epple et al., 2000; Masilamani et al.,
1999;Teixeira et al., 2006], the Na
+,K
+-ATPase pump
subunits [Kolla and Litwack, 2000] the channel-inducing
factor (CHIF), a member of the FXDY family, which
regulates pump activity in the colon [Brennan and Fuller,
1999;Wald et al., 1996], and the K-ras2 gene, expression
of which is also stimulated by aldosterone in the colon
[Brennan and Fuller, 2006].The best studied
aldosterone-induced gene in epithelial tissues is the
serine/threonine kinase SGK1, which plays a pivotal role
in sodium homeostasis, in that aldosterone-induced
expression of SGK1 strongly activates ENaC by
www.nursa.org  NRS  | 2007 |  Vol. 5 |  DOI: 10.1621/nrs.05012 | Page 6 of 16
Review The mineralocorticoid receptorphosphorylating the ubiquitin-ligase Nedd4-2 [Bhargava
et al., 2001; Chen et al., 1999; Naray-Fejes-Toth et al.,
1999].This phosphorylation impairs the interaction of
Nedd4-2 and ENaC, leading to degradation of ENaC by
the proteasome, and thus allowing a pool of channels to
remain at the apical membrane [Debonneville et al.,
2001].
Several lines of evidence suggest that SGK1 is not the
only mediator of aldosterone action.The
glucocorticoid-induced leucine zipper protein (GILZ),
initially identified as a transcription factor [Robert-Nicoud
et al., 2001], was subsequently shown to stimulate
ENaC-mediated Na
+ transport in the kidney by inhibiting
extracellular signal-regulated kinase (ERK) signaling
[Soundararajan et al., 2005]. A recent study has identified
novel early aldosterone-regulated mRNA in
microdissected mouse distal nephron by microarray.
Besides SGK1, the induced mRNA species include
Grem2, activating transcription factor 3, and the
ubiquitin-specific protease Usp2-45, which deubiquitylates
ENaC, and thus stimulates ENaC-mediated sodium
transport [Fakitsas et al., 2007]. Of importance, several
downregulated genes have also been identified, but their
roles in the regulation of ionic transport remain to be
established. KS-WNK1 (With No lysine K) is another
serine/threonine kinase which plays a crucial role in ENaC
activation [Naray-Fejes-Toth et al., 2004] upon
aldosterone exposure, stimulating the PI3 kinase pathway,
which directly activates SGK1 [Xu et al., 2005a; Xu et al.,
2005b]. Interestingly, other aldosterone-induced genes
have been reported so far, but their biological function
remains to be elucidated. For instance, NDRG2 (N-Myc
downstream regulated gene 2) [Boulkroun et al., 2002;
Wielputz et al., 2007], Endothelin-1 (ET-1) [Wong et al.,
2007] and the Plasminogen Activator Inhibitor-1 (PAI-1)
[Yuan et al., 2007] transcripts have been shown to be
specifically increased upon aldosterone exposure in the
kidney or distal colon.
Non-epithelial tissues
The discovery of new sites of MR expression in
non-epithelial tissues such as the heart, vasculature, brain
and adipocytes has led to identification of potential new
aldosterone target genes in these tissues with unexpected
biological functions (see Table 3). For instance, in aortic
endothelial cells, aldosterone was shown to increase
osteopontin and angiotensin-converting enzyme (ACE)
gene expression, which may be involved in the
development of endothelial dysfunction and vascular
injury induced by this steroid [Sugiyama et al., 2005a;
Sugiyama et al., 2005b]. Leopold et al. recently reported
that aldosterone impairs vascular reactivity by decreasing
endothelial glucose-6-phosphate dehydrogenase (G6PD)
expression and activity, which results in increased
oxidative stress and decreased NO levels [Leopold et al.,
2007]. In vascular smooth muscle cells, MDM2 was
identified as a novel mineralocorticoid-responsive gene
involved in aldosterone-induced vascular remodeling
[Nakamura et al., 2006]. In addition, MR activation in vitro
also directly enhances EGF-R gene expression, ultimately
contributing to an aldosterone-induced increase in
fibronectin abundance in aorta [Grossmann et al., 2007].
Several studies have demonstrated that aldosterone can
stimulate collagen (I, III and IV) gene expression in
cardiac [Brilla et al., 1994] or renal fibroblasts via
MR-mediated ERK1/2 activation pathway [Nagai et al.,
2005], which may contribute to the progression of
aldosterone-induced myocardial or tubulointerstitial
fibrosis.These adverse effects of aldosterone have
prompted a renewed interest in the use of MR antagonists
and for the identification of MR target genes, particularly
in the heart.
Very recently, a large number of target genes have been
identified in a cardiomyocyte cell line stably expressing
MR, including genes related to extracellular matrix
regulation (tenascin-X, ADAMTS1, PAI-1, UPAR, and
hyaluronic acid synthase-2), signaling, regulation of
vascular tone (RGS2, adrenomedullin) and inflammation
(orosomucoid) [Fejes-Toth and Naray-Fejes-Toth, 2007].
The role of aldosterone and MR in cell proliferation
[Stockand and Meszaros, 2003] and differentiation [Caprio
et al., 2007; Penfornis et al., 2000] is now well
documented. Physiological studies have demonstrated
the anti-apoptotic role of aldosterone and MR in
hippocampus degeneration. Indeed, the balance between
GR and MR seems to control limbic neuron fates [de Kloet
et al., 2005] and efforts have been made to identify
corticosteroid-responsive genes in the hippocampus
[Datson et al., 2001]. Interestingly, studies performed on
hippocampal neurons confirmed the protective effects of
MR on GR-induced apoptosis [Almeida et al., 2000;
Crochemore et al., 2005], and are in accordance with the
knockout mouse model for MR, which shows
degeneration of the hippocampus granule cells in
adulthood [Gass et al., 2000]. Recently, light has been
shed on the molecular basis of MR-prevented apoptosis
with molecular data showing that the MR NTD was able
to prevent all the features (modulation of pro versus
anti-apoptotic genes, and caspase inhibition) of
glucocorticoid-induced apoptosis in lymphocytes [Planey
et al., 2002], potentially through competition for common
coregulators (like ELL, FAF, or FLASH). In brown
adipocytes, it has been lately shown that aldosterone
treatment induced a marked decrease in expression and
function of mitochondrial uncoupling proteins UCP1 and
UCP3 [Viengchareun et al., 2001], providing additional
support for a role of MR in the control of energy
expenditure. Finally, aldosterone-activated MR also
promotes osteoblastic differentiation and mineralization
of vascular smooth muscle cells independently of BMP2
signaling [Jaffe et al., 2007], with the genes involved in
such effects yet to be identified.
Additional studies are needed to assess the contribution
of these potential target genes to the physiological and
pathophysiological effects of aldosterone in non-epithelial
tissues.
MR transgenic models
A better understanding of physiological MR actions has
been achieved by its transgenic expression in various
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Review The mineralocorticoid receptorFigure 2.  Model of MR action in a renal polarized epithelial cell. Aldosterone enters a target cell and binds MR, which translocates into the
nucleus. MR interacts with a HRE, recruits various transcriptional coregulators (Coregulators) to activate the transcriptional machinery (TM), and thus
alters expression of aldosterone target genes (in blue). At the apical membrane, ENaC (epithelial sodium channel), composed of three subunits (α, β
and γ), constitutes the rate-limiting step of apical Na
+ entry. Na
+ is then extruded into the basolateral space by the Na
+/K
+-ATPase pump, the activity of
which is modulated in the colon by the regulatory protein CHIF (corticosteroid hormone-induced factor). In the absence of aldosterone, ENaC proteins
interact with Nedd4-2, an ubiquitin-ligase which targets ENAC to proteosomal degradation. SGK1 (serum and glucocorticoid-regulated kinase) is a key
aldosterone-regulated target gene that plays a central role in sodium reabsorption. Upon aldosterone exposure, PDK1-activated kinase SGK1
phosphorylates Nedd4-2, which in turn dissociates from ENaC, increasing its apical membrane abundance. Usp2-45, a novel early aldosterone-induced
mRNA, is an ubiquitin-specific protease which deubiquitylates ENaC and thereby increases ENaC-mediated sodium transport. Other aldosterone-induced
genes included kidney specific KS-WNK1 (serine/threonine kinase With No K), K-Ras2, NDRG2 (N-myc down-stream regulated gene 2), GILZ
(glucocorticoid-induced leucine zipper), endothelin ET-1 and plasminogen activator inhibitor-1 (PAI-1).
Table 2.  MR target genes and their biological functions in epithelial tissues. This table presents the names of target genes, the expression
of which is regulated by MR in epithelial tissues.The function of the target gene products is listed, together with the corresponding references.
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Review The mineralocorticoid receptorTable 3.  MR target genes and their biological functions in non-epithelial tissues. This table shows the target genes, the expression of which
is upregulated or downregulated by MR in non-epithelial tissues.The functions of the target gene products are listed, together with the corresponding
references.
animal models. Such genetically engineered mice,
including MR gene inactivation, RNA interference and
MR overexpression, have been generated by several
groups. MR knockout mice, in which the MR DBD has
been disrupted, die around day 10 after birth from renal
sodium loss [Berger et al., 1998], prevented by exogenous
NaCl administration [Berger et al., 2000].The animals so
rescued show impaired neurogenesis and degeneration
of the hippocampus granule cells in adulthood, as
previously noted [Gass et al., 2000].This finding
emphasizes the role of MR in cell proliferation/apoptosis
balance in limbic structures. At variance with the MR KO
mouse model, the mouse aldosterone synthase gene
knockout is not lethal. As expected, ionic homeostasis is
altered in the absence of aldosterone, but as a
consequence, a high level of corticosterone and
angiotensin II seems to partially rescue sodium balance
[Makhanova et al., 2006], underscoring in this context the
importance of MR over aldosterone.
More recently, AQP2-Cre-MR mice with MR inactivation
in renal principal cells exhibited normal renal sodium
excretion associated with elevated aldosterone levels on
a standard diet. On a low-sodium diet, however, the mice
rapidly lost sodium consistent with the impaired induction
of ENaC channels in principal cells of the collecting duct
and late connecting tubule, in part functionally offset by
the late distal convoluted tubule and early connecting
tubule [Ronzaud et al., 2007]. Another MR conditional
knockout mouse with forebrain specific inactivation of MR
showed impaired spatial learning ability linked to
behavioral stereotype [Berger et al., 2006]. Brain-specific
MR inactivation compromised the rapid effect by
corticosterone, providing evidence that this nongenomic
effect is MR-mediated [Karst et al., 2005].
Mouse models of MR overexpression have also been
generated.The first used the human P1 proximal MR
promoter to drive human MR transgene expression in
most aldosterone target tissues (distal nephron, brain,
heart).These animals presented with enlarged kidneys
associated with renal tubular dilatation and normal blood
pressure, and developed mild dilated cardiomyopathy
associated with arrhythmia [Le Menuet et al., 2001]. In
addition, gene expression studies of these mice revealed
several alterations of cardiac- and renal-specific gene
expression such as ANF, SGK1, egr-1 [Le Menuet et al.,
2001]. Of interest, conditional cardiac MR overexpression
controlled by the α-myosin heavy chain promoter led to
life-threatening arrhythmias [Ouvrard-Pascaud et al.,
2005], consistent with the previous model. None of these
MR-overexpressing mice developed cardiac fibrosis,
clearly different from the cardiac phenotype previously
described for salt and aldosterone excess animal models
[Young et al., 1994], questioning the direct role of
cardiomyocyte MR in cardiac fibrosis. MR knockdown
experiments using the conditional expression of a MR
antisense mRNA was reported to induce cardiac fibrosis
and heart failure [Beggah et al., 2002].This phenotype
was somewhat unexpected, but could be related to an
imbalance between cardiac MR and GR levels, which
could ultimately lead to inappropriate corticosteroid
responses, reminiscent of the cardiac phenotype
observed with heart-specific overexpression of 11β-HSD2
[Qin et al., 2003]. Another transgenic mouse model with
a targeted overexpression of MR in the forebrain, using
the forebrain-specific calcium/calmodulin-dependent
protein kinase II α promoter, exhibited decreased
anxiety-like behavior associated with a diminution of
hippocampal GR protein and increased in serotonin
5HT-1a receptor levels [Rozeboom et al., 2007]. A
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in early postnatal death when the transgene was
expressed during gestation, associated with excessive
keratinocyte apoptosis. Additionally, postnatal transgene
expression led to alopecia and hair follicle dystrophy
[Sainte Marie et al., 2007].
MR and disease
Since the aldosterone-MR signaling pathway plays a
major role not only in the control of sodium and potassium
homeostasis, but also in other important physiological
processes, its involvement in numerous human diseases
is not surprising. Here, we will focus on diseases for which
a direct implication of MR has been documented. Among
them, the most important genetic disorder is the
autosomal dominant pseudohypoaldosteronism type 1
(adPHA1), which is caused, in most cases, by
heterozygous loss-of-function mutations of MR. First
described in 1958 [Cheek and Perry, 1958], this rare
life-threatening condition is characterized by renal
resistance to aldosterone action. Early in infancy, usually
during the first months of life, patients present with
dehydration and failure to thrive associated with massive
salt wasting, hyperkalemia and metabolic acidosis,
despite elevated plasma aldosterone and renin levels.
They require sodium supplementation during their early
years, which can be subsequently reduced, as adults are
usually asymptomatic in spite of high plasma aldosterone
and renin levels [Geller, 2005].To date, approximately
50 distinct mutations in the human MR gene responsible
for this syndrome have been described [Geller, 2005;
Geller et al., 1998; Pujo et al., 2007] and are summarized
in Figure 3.They include missense, nonsense, frameshift
and splice site mutations, as well as deletions spread
throughout the gene.These mutations are responsible
for either an early termination of translation with MR
truncation or a defect in MR activity (loss of LBD or DBD),
disruption of nucleocytoplasmic shuttling or alteration in
some transcriptional coregulator recruitment. Only
heterozygous mutations have been reported in humans,
suggesting that the homozygous state may be lethal in
utero.The loss of one allele results in haploinsufficiency,
sufficient to generate adPHA1 symptoms, thus underlining
the importance of a substantial MR protein level, most
notably during the neonatal period [Geller et al., 2006].
To date, there is only one mutation known to result in a
gain-of-function of MR, and it leads to a severe inherited
form of early-onset hypertension, which is exacerbated
during pregnancy [Geller et al., 2000].This single
mutation S810L in the LBD causes a constitutive MR
activation, as well as illicit activation of MR by
progesterone and other steroids, including cortisone,
11-dehydrocorticosterone and the mineralocorticoid
antagonist spironolactone [Geller et al., 2000; Pinon et
al., 2004; Rafestin-Oblin et al., 2003].
Besides pathogenic mutations of the hMR gene, common
MR polymorphisms have been described and seem to
be mostly related to modulation of stress responsiveness.
In the brain, where 11β-HSD2 is not expressed except
in discrete brain areas, MR may be sensitive to cortisol
level variations induced by stress.Thus, the MR allele
I180V, which has a frequency of approximately 15%
varying with ethnic background [Arai et al., 1999; Balsamo
et al., 2007], has been found associated with enhanced
endocrine and autonomic responses to a psychological
stressor, without any modification of sodium homeostasis
or blood pressure [DeRijk et al., 2006]. Given this finding,
other polymorphisms deserve to be characterized in terms
of functional consequences, both for sodium handling or
clinical implications.
Besides genetic diseases, the prominent role played by
MR in the pathogenesis of cardiac dysfunction in humans
is now well documented. Indeed, large clinical trials
(RALES, EPHESUS, 4E) have demonstrated the major
benefits of anti-mineralocorticoid therapy, such as
spironolactone and eplerenone, in reducing the mortality
and improving the prognosis of heart failure patients [Pitt
et al., 1999] or after post-acute myocardial infarction [Pitt
et al., 2003]. However, the molecular mechanisms
involved in the protective effects of these MR antagonists
remain to be fully characterized. It is noteworthy that a
recent report shows that MR activation is a critical factor
in the early pathogenesis of renal disease in both type 1
and type 2 diabetes mellitus [Guo et al., 2006].
Ligands
In human, aldosterone is the physiological ligand of MR,
most notably for epithelial MR.This hormone is
synthesized in the zona glomerulosa of adrenal cortex
under the regulation of angiotensin II, ACTH and serum
potassium concentration. Another important physiological
ligand of MR is cortisol (corticosterone in rodents), which
has the same affinity for MR even though the dynamic
binding parameters and the functional properties of
glucocorticoid-MR complexes are somehow different from
that of aldosterone-MR [Kitagawa et al., 2002; Lombes
et al., 1994b].The most potent MR-protective mechanism
against MR activation by glucocorticoid hormones is
11β-HSD2, the NAD-dependent enzyme which converts
cortisol into its inactive metabolite cortisone, in epithelial
and vascular target tissues. Deoxycorticosterone (most
notably in fish) [Sturm et al., 2005], as well as other
glucocorticosteroid compounds (dexamethasone,
fludrocortisone), act as mineralocorticoid agonists, at
least in vitro. It is now clear that progesterone and
androgens and their derivatives could also bind MR and
exert partial agonist and antagonist effects depending on
the cellular context [Marissal-Arvy et al., 2004; Quinkler
et al., 2002; Quinkler et al., 2003;Takeda et al., 2007].
Several mineralocorticoid antagonists, such as
spironolactone and the more selective eplerenone [Pitt
et al., 2003], have been developed and are currently used
as antihypertensive and cardiovascular protective agents.
Drospirenone is a novel progestogen with considerable
MR antagonist activity [Oelkers, 2004].
Selective mineralocorticoid receptor modulators, either
steroid-derived compounds or alternatively nonsteroidal
scaffold ligands, should ultimately produce beneficial
effects mediated by transactivation or transrepression of
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Review The mineralocorticoid receptorFigure 3. Schematic localization of MR mutations causing pseudohypoaldosteronism type 1 and polymorphisms in the human NR3C2 gene.
Nucleotide and amino acid numbering is indicated in reference to the published cDNA, where +1 is the A of the translational initiation codon (Arriza
et al., 1987). Fs, frameshift (red); X, stop codon (blue); missense (green); sp alt, splice alteration (purple); polymorphism (black).
MR in a tissue-dependent manner. Ideally, a MR
modulator would have neuronal anti-apoptotic effects and
efficient protective effects on renal and cardiovascular
systems.
Conclusions
It now appears that the roles of MR extend far beyond
control of fluid and electrolyte homeostasis, being involved
in (patho)physiological processes as diverse as
cardiovascular remodeling, fat storage, energy balance,
and mammalian behavior. MR transgenic mouse models
have been and will continue to be extremely useful in
unraveling these new aspects of MR biology. MR action
must be seen in the context of its functional interaction
with transcriptional coregulators, for which physiological
roles are not redundant as initially thought, but are quite
specific, as exemplified by members of the SRC family.
The combinatorial tissue distribution of MR and its
coregulators thus provides subtle cell-dependent tuning
of MR target gene regulation and should also offer new
insights into the molecular mechanisms of MR selectivity.
Furthermore, recent evidence supports cross-talk between
SR and other signaling pathways (like MAPK, src, STAT);
the implications for MR remain to be established.The
regulation of MR expression in non-epithelial tissues may
differ from that in epithelia. Determining the transcriptional
factors orchestrating MR expression constitutes an
interesting challenge in terms of better understanding
MR-mediated responses, in addition to its potential
relevance to pathophysiological disorders. Altogether,
the aim of continuing research is to improve
comprehension of MR-mediated signaling, both at the
genomic and non-genomic levels, in order to propose
new therapeutic strategies for human diseases.
Acknowledgements
We acknowledge John Funder for helpful discussions, support over the
years and his critical reading and editing of this manuscript.We also want
to thank our colleagues and collaborators for their help and
encouragement in this exciting research area of nuclear receptor biology.
We would like to apologize to any investigators who have made
contributions in the mineralocorticoid receptor field and whose works may
have been omitted. Finally, we are indebted to INSERM and Université
Paris-Sud 11 for funding.
References
Almeida, O. F., Conde, G. L., Crochemore, C., Demeneix, B. A., Fischer,
D., Hassan, A. H., Meyer, M., Holsboer, F. and Michaelidis, T. M. (2000)
Subtle shifts in the ratio between pro- and antiapoptotic molecules after
activation of corticosteroid receptors decide neuronal fate Faseb J 14,
779-90.
Alnemri, E. S., Maksymowych, A. B., Robertson, N. M. and Litwack, G.
(1991) Overexpression and characterization of the human
mineralocorticoid receptor J Biol Chem 266, 18072-81.
Arai, K., Zachman, K., Shibasaki, T. and Chrousos, G. P. (1999)
Polymorphisms of amiloride-sensitive sodium channel subunits in five
sporadic cases of pseudohypoaldosteronism: do they have pathologic
potential? J Clin Endocrinol Metab 84, 2434-7.
Armanini, D., Strasser, T. and Weber, P. C. (1985) Characterization of
aldosterone binding sites in circulating human mononuclear leukocytes
Am J Physiol 248, E388-90.
Arriza, J. L., Weinberger, C., Cerelli, G., Glaser, T. M., Handelin, B. L.,
Housman, D. E. and Evans, R. M. (1987) Cloning of human
mineralocorticoid receptor complementary DNA: structural and functional
kinship with the glucocorticoid receptor Science 237, 268-75.
Baker, M. E., Chandsawangbhuwana, C. and Ollikainen, N. (2007)
Structural analysis of the evolution of steroid specificity in the
mineralocorticoid and glucocorticoid receptors BMC Evol Biol 7, 24.
Balsamo, A., Cicognani, A., Gennari, M., Sippell, W. G., Menabo, S.,
Baronio, F. and Riepe, F. G. (2007) Functional characterization of naturally
occurring NR3C2 gene mutations in Italian patients suffering from
pseudohypoaldosteronism type 1 Eur J Endocrinol 156, 249-56.
Barnett, C. A. and Pritchett, E. L. (1988) Detection of corticosteroid type
I binding sites in heart Mol Cell Endocrinol 56, 191-8.
Beggah, A.T., Escoubet, B., Puttini, S., Cailmail, S., Delage, V.,
Ouvrard-Pascaud, A., Bocchi, B., Peuchmaur, M., Delcayre, C., Farman,
N. and Jaisser, F. (2002) Reversible cardiac fibrosis and heart failure
induced by conditional expression of an antisense mRNA of the
mineralocorticoid receptor in cardiomyocytes Proc Natl Acad Sci U S A
99, 7160-5.
www.nursa.org  NRS  | 2007 |  Vol. 5 |  DOI: 10.1621/nrs.05012 | Page 11 of 16
Review The mineralocorticoid receptorBens, M., Vallet, V., Cluzeaud, F., Pascual-Letallec, L., Kahn, A.,
Rafestin-Oblin, M. E., Rossier, B. C. and Vandewalle, A. (1999)
Corticosteroid-dependent sodium transport in a novel immortalized mouse
collecting duct principal cell line J Am Soc Nephrol 10, 923-34.
Berger, S., Wolfer, D. P., Selbach, O., Alter, H., Erdmann, G., Reichardt,
H. M., Chepkova, A. N., Welzl, H., Haas, H. L., Lipp, H. P. and Schutz,
G. (2006) Loss of the limbic mineralocorticoid receptor impairs behavioral
plasticity Proc Natl Acad Sci U S A 103, 195-200.
Berger, S., Bleich, M., Schmid, W., Greger, R. and Schutz, G. (2000)
Mineralocorticoid receptor knockout mice: lessons on Na+ metabolism
Kidney Int 57, 1295-8.
Berger, S., Bleich, M., Schmid, W., Cole, T. J., Peters, J., Watanabe, H.,
Kriz, W., Warth, R., Greger, R. and Schutz, G. (1998) Mineralocorticoid
receptor knockout mice: pathophysiology of Na+ metabolism Proc Natl
Acad Sci U S A 95, 9424-9.
Bhargava, A., Fullerton, M. J., Myles, K., Purdy, T. M., Funder, J.W.,
Pearce, D. and Cole, T. J. (2001) The serum- and glucocorticoid-induced
kinase is a physiological mediator of aldosterone action Endocrinology
142, 1587-94.
Binart, N., Lombes, M., Rafestin-Oblin, M. E. and Baulieu, E. E. (1991)
Characterization of human mineralocorticosteroid receptor expressed in
the baculovirus system Proc Natl Acad Sci U S A 88, 10681-5.
Binart, N., Lombes, M. and Baulieu, E. E. (1995) Distinct functions of the
90 kDa heat-shock protein (hsp90) in oestrogen and mineralocorticosteroid
receptor activity: effects of hsp90 deletion mutants Biochem J 311 ( Pt
3), 797-804.
Black, B. E., Holaska, J. M., Rastinejad, F. and Paschal, B. M. (2001)
DNA binding domains in diverse nuclear receptors function as nuclear
export signals Curr Biol 11, 1749-58.
Bledsoe, R. K., Madauss, K. P., Holt, J. A., Apolito, C. J., Lambert, M. H.,
Pearce, K. H., Stanley, T. B., Stewart, E. L., Trump, R. P., Willson, T. M.
and Williams, S. P. (2005) A ligand-mediated hydrogen bond network
required for the activation of the mineralocorticoid receptor J Biol Chem
280, 31283-93.
Bookout, A. L., Jeong, Y., Downes, M., Yu, R.T., Evans, R. M. and
Mangelsdorf, D. J. (2006) Anatomical profiling of nuclear receptor
expression reveals a hierarchical transcriptional network Cell 126, 789-99.
Boulkroun, S., Fay, M., Zennaro, M. C., Escoubet, B., Jaisser, F.,
Blot-Chabaud, M., Farman, N. and Courtois-Coutry, N. (2002)
Characterization of rat NDRG2 (N-Myc downstream regulated gene 2),
a novel early mineralocorticoid-specific induced gene J Biol Chem 277,
31506-15.
Brennan, F. E. and Fuller, P. J. (1999) Acute regulation by corticosteroids
of channel-inducing factor gene messenger ribonucleic acid in the distal
colon Endocrinology 140, 1213-8.
Brennan, F. E. and Fuller, P. J. (2006) Mammalian K-ras2 is a
corticosteroid-induced gene in vivo Endocrinology 147, 2809-16.
Bridgham, J.T., Carroll, S. M. and Thornton, J.W. (2006) Evolution of
hormone-receptor complexity by molecular exploitation Science 312,
97-101.
Brilla, C. G., Zhou, G., Matsubara, L. and Weber, K.T. (1994) Collagen
metabolism in cultured adult rat cardiac fibroblasts: response to
angiotensin II and aldosterone J Mol Cell Cardiol 26, 809-20.
Bruner, K. L., Derfoul, A., Robertson, N. M., Guerriero, G.,
Fernandes-Alnemri, T., Alnemri, E. S. and Litwack, G. (1997) The
unliganded mineralocorticoid receptor is associated with heat shock
proteins 70 and 90 and the immunophilin FKBP-52 Recept Signal
Transduct 7, 85-98.
Canessa, C. M., Schild, L., Buell, G., Thorens, B., Gautschi, I.,
Horisberger, J. D. and Rossier, B. C. (1994) Amiloride-sensitive epithelial
Na+ channel is made of three homologous subunits Nature 367, 463-7.
Caprio, M., Feve, B., Claes, A., Viengchareun, S., Lombes, M. and
Zennaro, M. C. (2007) Pivotal role of the mineralocorticoid receptor in
corticosteroid-induced adipogenesis Faseb J 21, 2185-94.
Castren, M., Patchev, V. K., Almeida, O. F., Holsboer, F., Trapp, T. and
Castren, E. (1995) Regulation of rat mineralocorticoid receptor expression
in neurons by progesterone Endocrinology 136, 3800-6.
Cheek, D. B. and Perry, J.W. (1958) A salt wasting syndrome in infancy
Arch Dis Child 33, 252-6.
Chen, S.Y., Bhargava, A., Mastroberardino, L., Meijer, O. C., Wang, J.,
Buse, P., Firestone, G. L., Verrey, F. and Pearce, D. (1999) Epithelial
sodium channel regulated by aldosterone-induced protein sgk Proc Natl
Acad Sci U S A 96, 2514-9.
Crochemore, C., Lu, J., Wu, Y., Liposits, Z., Sousa, N., Holsboer, F. and
Almeida, O. F. (2005) Direct targeting of hippocampal neurons for
apoptosis by glucocorticoids is reversible by mineralocorticoid receptor
activation Mol Psychiatry 10, 790-8.
Datson, N. A., van der Perk, J., de Kloet, E. R. and Vreugdenhil, E. (2001)
Identification of corticosteroid-responsive genes in rat hippocampus using
serial analysis of gene expression Eur J Neurosci 14, 675-89.
de Kloet, E. R. (2003) Hormones, brain and stress Endocr Regul 37,
51-68.
de Kloet, E. R., Joels, M. and Holsboer, F. (2005) Stress and the brain:
from adaptation to disease Nat Rev Neurosci 6, 463-75.
Debonneville, C., Flores, S.Y., Kamynina, E., Plant, P. J., Tauxe, C.,
Thomas, M. A., Munster, C., Chraibi, A., Pratt, J. H., Horisberger, J. D.,
Pearce, D., Loffing, J. and Staub, O. (2001) Phosphorylation of Nedd4-2
by Sgk1 regulates epithelial Na(+) channel cell surface expression Embo
J 20, 7052-9.
DeRijk, R. H., Wust, S., Meijer, O. C., Zennaro, M. C., Federenko, I. S.,
Hellhammer, D. H., Giacchetti, G., Vreugdenhil, E., Zitman, F. G. and de
Kloet, E. R. (2006) A common polymorphism in the mineralocorticoid
receptor modulates stress responsiveness J Clin Endocrinol Metab 91,
5083-9.
Duval, D. and Funder, J.W. (1974) The binding of tritiated aldosterone
in the rat liver cytosol Endocrinology 94, 575-9.
Edwards, C. R., Stewart, P. M., Burt, D., Brett, L., McIntyre, M. A., Sutanto,
W. S., de Kloet, E. R. and Monder, C. (1988) Localisation of 11
β-hydroxysteroid dehydrogenase--tissue specific protector of the
mineralocorticoid receptor Lancet 2, 986-9.
Epple, H. J., Amasheh, S., Mankertz, J., Goltz, M., Schulzke, J. D. and
Fromm, M. (2000) Early aldosterone effect in distal colon by transcriptional
regulation of ENaC subunits Am J Physiol Gastrointest Liver Physiol 278,
G718-24.
Fagart, J., Huyet, J., Pinon, G. M., Rochel, M., Mayer, C. and
Rafestin-Oblin, M. E. (2005) Crystal structure of a mutant mineralocorticoid
receptor responsible for hypertension Nat Struct Mol Biol 12, 554-5.
Fakitsas, P., Adam, G., Daidie, D., van Bemmelen, M. X., Fouladkou, F.,
Patrignani, A., Wagner, U., Warth, R., Camargo, S. M., Staub, O. and
Verrey, F. (2007) Early aldosterone-induced gene product regulates the
epithelial sodium channel by deubiquitylation J Am Soc Nephrol 18,
1084-92.
Fejes-Toth, G. and Naray-Fejes-Toth, A. (2007) Early
aldosterone-regulated genes in cardiomyocytes: clues to cardiac
remodeling? Endocrinology 148, 1502-10.
Freiman, R. N. and Tjian, R. (2003) Regulating the regulators: lysine
modifications make their mark Cell 112, 11-7.
Fu, M., Sun, T., Bookout, A. L., Downes, M., Yu, R.T., Evans, R. M. and
Mangelsdorf, D. J. (2005) A Nuclear Receptor Atlas: 3T3-L1 adipogenesis
Mol Endocrinol 19, 2437-50.
www.nursa.org  NRS  | 2007 |  Vol. 5 |  DOI: 10.1621/nrs.05012 | Page 12 of 16
Review The mineralocorticoid receptorFunder, J.W., Pearce, P.T., Smith, R. and Smith, A. I. (1988)
Mineralocorticoid action: target tissue specificity is enzyme, not receptor,
mediated Science 242, 583-5.
Funder, J.W., Feldman, D. and Edelman, I. S. (1972) Specific aldosterone
binding in rat kidney and parotid J Steroid Biochem 3, 209-18.
Funder, J.W. (2005) The nongenomic actions of aldosterone Endocr Rev
26, 313-21.
Furuta, H., Mori, N., Sato, C., Hoshikawa, H., Sakai, S., Iwakura, S. and
Doi, K. (1994) Mineralocorticoid type I receptor in the rat cochlea: mRNA
identification by polymerase chain reaction (PCR) and in situ hybridization
Hear Res 78, 175-80.
Fuse, H., Kitagawa, H. and Kato, S. (2000) Characterization of
transactivational property and coactivator mediation of rat mineralocorticoid
receptor activation function-1 (AF-1) Mol Endocrinol 14, 889-99.
Gass, P., Kretz, O., Wolfer, D. P., Berger, S., Tronche, F., Reichardt, H.
M., Kellendonk, C., Lipp, H. P., Schmid, W. and Schutz, G. (2000) Genetic
disruption of mineralocorticoid receptor leads to impaired neurogenesis
and granule cell degeneration in the hippocampus of adult mice EMBO
Rep 1, 447-51.
Geerling, J. C., Kawata, M. and Loewy, A. D. (2006) Aldosterone-sensitive
neurons in the rat central nervous system J Comp Neurol 494, 515-27.
Geller, D. S., Farhi, A., Pinkerton, N., Fradley, M., Moritz, M., Spitzer, A.,
Meinke, G., Tsai, F.T., Sigler, P. B. and Lifton, R. P. (2000) Activating
mineralocorticoid receptor mutation in hypertension exacerbated by
pregnancy Science 289, 119-23.
Geller, D. S., Zhang, J., Zennaro, M. C., Vallo-Boado, A.,
Rodriguez-Soriano, J., Furu, L., Haws, R., Metzger, D., Botelho, B.,
Karaviti, L., Haqq, A. M., Corey, H., Janssens, S., Corvol, P. and Lifton,
R. P. (2006) Autosomal dominant pseudohypoaldosteronism type 1:
mechanisms, evidence for neonatal lethality, and phenotypic expression
in adults J Am Soc Nephrol 17, 1429-36.
Geller, D. S. (2005) Mineralocorticoid resistance Clin Endocrinol (Oxf)
62, 513-20.
Geller, D. S., Rodriguez-Soriano, J., Vallo Boado, A., Schifter, S., Bayer,
M., Chang, S. S. and Lifton, R. P. (1998) Mutations in the mineralocorticoid
receptor gene cause autosomal dominant pseudohypoaldosteronism type
I Nat Genet 19, 279-81.
Greenwood, A. K., Butler, P. C., White, R. B., DeMarco, U., Pearce, D.
and Fernald, R. D. (2003) Multiple corticosteroid receptors in a teleost
fish: distinct sequences, expression patterns, and transcriptional activities
Endocrinology 144, 4226-36.
Grossmann, C., Krug, A.W., Freudinger, R., Mildenberger, S., Voelker,
K. and Gekle, M. (2007) Aldosterone-induced EGFR expression:
interaction between the human mineralocorticoid receptor and the human
EGFR promoter Am J Physiol Endocrinol Metab 292, E1790-800.
Guo, C., Martinez-Vasquez, D., Mendez, G. P., Toniolo, M. F., Yao, T.
M., Oestreicher, E. M., Kikuchi, T., Lapointe, N., Pojoga, L., Williams, G.
H., Ricchiuti, V. and Adler, G. K. (2006) Mineralocorticoid receptor
antagonist reduces renal injury in rodent models of types 1 and 2 diabetes
mellitus Endocrinology 147, 5363-73.
Han, F., Ozawa, H., Matsuda, K., Nishi, M. and Kawata, M. (2005)
Colocalization of mineralocorticoid receptor and glucocorticoid receptor
in the hippocampus and hypothalamus Neurosci Res 51, 371-81.
Herman, J. P., Patel, P. D., Akil, H. and Watson, S. J. (1989) Localization
and regulation of glucocorticoid and mineralocorticoid receptor messenger
RNAs in the hippocampal formation of the rat Mol Endocrinol 3, 1886-94.
Hirasawa, G., Takeyama, J., Sasano, H., Fukushima, K., Suzuki, T.,
Muramatu, Y., Darnel, A. D., Kaneko, C., Hiwatashi, N., Toyota, T.,
Nagura, H. and Krozowski, Z. S. (2000) 11Beta-hydroxysteroid
dehydrogenase type II and mineralocorticoid receptor in human placenta
J Clin Endocrinol Metab 85, 1306-9.
Hirschberg, D., Jagerbrink, T., Samskog, J., Gustafsson, M., Stahlberg,
M., Alvelius, G., Husman, B., Carlquist, M., Jornvall, H. and Bergman, T.
(2004) Detection of phosphorylated peptides in proteomic analyses using
microfluidic compact disk technology Anal Chem 76, 5864-71.
Hodgson, Z. G., Meddle, S. L., Roberts, M. L., Buchanan, K. L., Evans,
M. R., Metzdorf, R., Gahr, M. and Healy, S. D. (2007) Spatial ability is
impaired and hippocampal mineralocorticoid receptor mRNA expression
reduced in zebra finches (Taeniopygia guttata) selected for acute high
corticosterone response to stress Proc Biol Sci 274, 239-45.
Horisberger, J. D., Lemas, V., Kraehenbuhl, J. P. and Rossier, B. C.
(1991) Structure-function relationship of Na,K-ATPase Annu Rev Physiol
53, 565-84.
Hultman, M. L., Krasnoperova, N.V., Li, S., Du, S., Xia, C., Dietz, J. D.,
Lala, D. S., Welsch, D. J. and Hu, X. (2005) The ligand-dependent
interaction of mineralocorticoid receptor with coactivator and corepressor
peptides suggests multiple activation mechanisms Mol Endocrinol 19,
1460-73.
Hu, X. and Funder, J.W. (2006) The evolution of mineralocorticoid
receptors Mol Endocrinol 20, 1471-8.
Huyet, J., Pinon, G. M., Fay, M. R., Fagart, J. and Rafestin-Oblin, M. E.
(2007) Structural basis of spirolactone recognition by the mineralocorticoid
receptor Mol Pharmacol 72, 563-71.
Iniguez-Lluhi, J. A. and Pearce, D. (2000) A common motif within the
negative regulatory regions of multiple factors inhibits their transcriptional
synergy Mol Cell Biol 20, 6040-50.
Jaffe, I. Z., Tintut, Y., Newfell, B. G., Demer, L. L. and Mendelsohn, M.
E. (2007) Mineralocorticoid receptor activation promotes vascular cell
calcification Arterioscler Thromb Vasc Biol 27, 799-805.
Jalaguier, S., Mornet, D., Mesnier, D., Leger, J. J. and Auzou, G. (1996)
Human mineralocorticoid receptor interacts with actin under
mineralocorticoid ligand modulation FEBS Lett 384, 112-6.
Jorgensen, P. L. (1986) Structure, function and regulation of Na,K-ATPase
in the kidney Kidney Int 29, 10-20.
Karst, H., Berger, S., Turiault, M., Tronche, F., Schutz, G. and Joels, M.
(2005) Mineralocorticoid receptors are indispensable for nongenomic
modulation of hippocampal glutamate transmission by corticosterone
Proc Natl Acad Sci U S A 102, 19204-7.
Kenouch, S., Lombes, M., Delahaye, F., Eugene, E., Bonvalet, J. P. and
Farman, N. (1994) Human skin as target for aldosterone: coexpression
of mineralocorticoid receptors and 11 β-hydroxysteroid dehydrogenase
J Clin Endocrinol Metab 79, 1334-41.
Kitagawa, H., Yanagisawa, J., Fuse, H., Ogawa, S., Yogiashi, Y., Okuno,
A., Nagasawa, H., Nakajima, T., Matsumoto, T. and Kato, S. (2002)
Ligand-selective potentiation of rat mineralocorticoid receptor activation
function 1 by a CBP-containing histone acetyltransferase complex Mol
Cell Biol 22, 3698-706.
Kolla, V. and Litwack, G. (2000) Transcriptional regulation of the human
Na/K ATPase via the human mineralocorticoid receptor Mol Cell Biochem
204, 35-40.
Krozowski, Z. S., Rundle, S. E., Wallace, C., Castell, M. J., Shen, J. H.,
Dowling, J., Funder, J.W. and Smith, A. I. (1989) Immunolocalization of
renal mineralocorticoid receptors with an antiserum against a peptide
deduced from the complementary deoxyribonucleic acid sequence
Endocrinology 125, 192-8.
Krozowski, Z. and Funder, J.W. (1981) Mineralocorticoid receptors in
the rat lung Endocrinology 109, 1811-3.
Kwak, S. P., Patel, P. D., Thompson, R. C., Akil, H. and Watson, S. J.
(1993) 5'-Heterogeneity of the mineralocorticoid receptor messenger
ribonucleic acid: differential expression and regulation of splice variants
within the rat hippocampus Endocrinology 133, 2344-50.
www.nursa.org  NRS  | 2007 |  Vol. 5 |  DOI: 10.1621/nrs.05012 | Page 13 of 16
Review The mineralocorticoid receptorLai, M., McCormick, J. A., Chapman, K. E., Kelly, P. A., Seckl, J. R. and
Yau, J. L. (2003) Differential regulation of corticosteroid receptors by
monoamine neurotransmitters and antidepressant drugs in primary
hippocampal culture Neuroscience 118, 975-84.
Le Menuet, D., Isnard, R., Bichara, M., Viengchareun, S., Muffat-Joly,
M., Walker, F., Zennaro, M. C. and Lombes, M. (2001) Alteration of cardiac
and renal functions in transgenic mice overexpressing human
mineralocorticoid receptor J Biol Chem 276, 38911-20.
Le Menuet, D., Viengchareun, S., Muffat-Joly, M., Zennaro, M. C. and
Lombes, M. (2004) Expression and function of the human
mineralocorticoid receptor: lessons from transgenic mouse models Mol
Cell Endocrinol 217, 127-36.
Le Menuet, D., Viengchareun, S., Penfornis, P., Walker, F., Zennaro, M.
C. and Lombes, M. (2000) Targeted oncogenesis reveals a distinct
tissue-specific utilization of alternative promoters of the human
mineralocorticoid receptor gene in transgenic mice J Biol Chem 275,
7878-86.
Le Moellic, C., Ouvrard-Pascaud, A., Capurro, C., Cluzeaud, F., Fay, M.,
Jaisser, F., Farman, N. and Blot-Chabaud, M. (2004) Early nongenomic
events in aldosterone action in renal collecting duct cells: PKCalpha
activation, mineralocorticoid receptor phosphorylation, and cross-talk with
the genomic response J Am Soc Nephrol 15, 1145-60.
Leopold, J. A., Dam, A., Maron, B. A., Scribner, A.W., Liao, R., Handy,
D. E., Stanton, R. C., Pitt, B. and Loscalzo, J. (2007) Aldosterone impairs
vascular reactivity by decreasing glucose-6-phosphate dehydrogenase
activity Nat Med 13, 189-97.
Lin, J., Handschin, C. and Spiegelman, B. M. (2005) Metabolic control
through the PGC-1 family of transcription coactivators Cell Metab 1,
361-70.
Lin, D.Y., Huang, Y. S., Jeng, J. C., Kuo, H.Y., Chang, C. C., Chao, T.
T., Ho, C. C., Chen, Y. C., Lin, T. P., Fang, H. I., Hung, C. C., Suen, C.
S., Hwang, M. J., Chang, K. S., Maul, G. G. and Shih, H. M. (2006) Role
of SUMO-interacting motif in Daxx SUMO modification, subnuclear
localization, and repression of sumoylated transcription factors Mol Cell
24, 341-54.
Li, Y., Suino, K., Daugherty, J. and Xu, H. E. (2005) Structural and
biochemical mechanisms for the specificity of hormone binding and
coactivator assembly by mineralocorticoid receptor Mol Cell 19, 367-80.
Liu, W., Wang, J., Sauter, N. K. and Pearce, D. (1995) Steroid receptor
heterodimerization demonstrated in vitro and in vivo Proc Natl Acad Sci
U S A 92, 12480-4.
Lombes, M., Claire, M., Pinto, M., Michaud, A. and Rafestin-Oblin, M. E.
(1984) Aldosterone binding in the human colon carcinoma cell line HT29:
correlation with cell differentiation J Steroid Biochem 20, 329-33.
Lombes, M., Binart, N., Delahaye, F., Baulieu, E. E. and Rafestin-Oblin,
M. E. (1994a) Differential intracellular localization of human
mineralocorticosteroid receptor on binding of agonists and antagonists
Biochem J 302 ( Pt 1), 191-7.
Lombes, M., Oblin, M. E., Gasc, J. M., Baulieu, E. E., Farman, N. and
Bonvalet, J. P. (1992) Immunohistochemical and biochemical evidence
for a cardiovascular mineralocorticoid receptor Circ Res 71, 503-10.
Lombes, M., Farman, N., Oblin, M. E., Baulieu, E. E., Bonvalet, J. P.,
Erlanger, B. F. and Gasc, J. M. (1990) Immunohistochemical localization
of renal mineralocorticoid receptor by using an anti-idiotypic antibody that
is an internal image of aldosterone Proc Natl Acad Sci U S A 87, 1086-8.
Lombes, M., Kenouch, S., Souque, A., Farman, N. and Rafestin-Oblin,
M. E. (1994b) The mineralocorticoid receptor discriminates aldosterone
from glucocorticoids independently of the 11 β-hydroxysteroid
dehydrogenase Endocrinology 135, 834-40.
Lu, N. Z. and Cidlowski, J. A. (2005) Translational regulatory mechanisms
generate N-terminal glucocorticoid receptor isoforms with unique
transcriptional target genes Mol Cell 18, 331-42.
Makhanova, N., Sequeira-Lopez, M. L., Gomez, R. A., Kim, H. S. and
Smithies, O. (2006) Disturbed homeostasis in sodium-restricted mice
heterozygous and homozygous for aldosterone synthase gene disruption
Hypertension 48, 1151-9.
Marissal-Arvy, N., Lombes, M., Petterson, J., Moisan, M. P. and Mormede,
P. (2004) Gain of function mutation in the mineralocorticoid receptor of
the Brown Norway rat J Biol Chem 279, 39232-9.
Marver, D., Stewart, J., Funder, J.W., Feldman, D. and Edelman, I. S.
(1974) Renal aldosterone receptors: studies with (3H)aldosterone and
the anti-mineralocorticoid (3H)spirolactone (SC-26304) Proc Natl Acad
Sci U S A 71, 1431-5.
Masilamani, S., Kim, G. H., Mitchell, C., Wade, J. B. and Knepper, M. A.
(1999) Aldosterone-mediated regulation of ENaC α, β, and γ subunit
proteins in rat kidney J Clin Invest 104, R19-23.
Metivier, R., Penot, G., Hubner, M. R., Reid, G., Brand, H., Kos, M. and
Gannon, F. (2003) Estrogen receptor-α directs ordered, cyclical, and
combinatorial recruitment of cofactors on a natural target promoter Cell
115, 751-63.
Mirshahi, M., Mirshahi, A., Sedighian, R., Hecquet, C., Faure, J. P. and
Agarwal, M. K. (1997) Immunochemical demonstration of the
mineralocorticoid receptor in ocular tissues Neuroendocrinology 65, 70-8.
Miyata, K., Rahman, M., Shokoji, T., Nagai, Y., Zhang, G. X., Sun, G. P.,
Kimura, S., Yukimura, T., Kiyomoto, H., Kohno, M., Abe, Y. and
Nishiyama, A. (2005) Aldosterone stimulates reactive oxygen species
production through activation of NADPH oxidase in rat mesangial cells J
Am Soc Nephrol 16, 2906-12.
Morrison, N., Harrap, S. B., Arriza, J. L., Boyd, E. and Connor, J. M. (1990)
Regional chromosomal assignment of the human mineralocorticoid
receptor gene to 4q31.1 Hum Genet 85, 130-2.
Nagai, Y., Miyata, K., Sun, G. P., Rahman, M., Kimura, S., Miyatake, A.,
Kiyomoto, H., Kohno, M., Abe, Y., Yoshizumi, M. and Nishiyama, A. (2005)
Aldosterone stimulates collagen gene expression and synthesis via
activation of ERK1/2 in rat renal fibroblasts Hypertension 46, 1039-45.
Nakamura, Y., Suzuki, S., Suzuki, T., Ono, K., Miura, I., Satoh, F., Moriya,
T., Saito, H., Yamada, S., Ito, S. and Sasano, H. (2006) MDM2: a novel
mineralocorticoid-responsive gene involved in aldosterone-induced human
vascular structural remodeling Am J Pathol 169, 362-71.
Naray-Fejes-Toth, A. and Fejes-Toth, G. (2007) Novel mouse strain with
Cre recombinase in 11beta-hydroxysteroid dehydrogenase-2-expressing
cells Am J Physiol Renal Physiol 292, F486-94.
Naray-Fejes-Toth, A., Canessa, C., Cleaveland, E. S., Aldrich, G. and
Fejes-Toth, G. (1999) sgk is an aldosterone-induced kinase in the renal
collecting duct. Effects on epithelial na+ channels J Biol Chem 274,
16973-8.
Naray-Fejes-Toth, A., Snyder, P. M. and Fejes-Toth, G. (2004) The
kidney-specific WNK1 isoform is induced by aldosterone and stimulates
epithelial sodium channel-mediated Na+ transport Proc Natl Acad Sci U
S A 101, 17434-9.
Nishiyama, A., Yao, L., Fan, Y., Kyaw, M., Kataoka, N., Hashimoto, K.,
Nagai, Y., Nakamura, E., Yoshizumi, M., Shokoji, T., Kimura, S., Kiyomoto,
H., Tsujioka, K., Kohno, M., Tamaki, T., Kajiya, F. and Abe, Y. (2005)
Involvement of aldosterone and mineralocorticoid receptors in rat
mesangial cell proliferation and deformability Hypertension 45, 710-6.
Oelkers, W. (2004) Drospirenone, a progestogen with antimineralocorticoid
properties: a short review Mol Cell Endocrinol 217, 255-61.
O'Malley, B.W. (2007) Coregulators: from whence came these "master
genes" Mol Endocrinol 21, 1009-13.
Onate, S. A., Tsai, S.Y., Tsai, M. J. and O'Malley, B.W. (1995) Sequence
and characterization of a coactivator for the steroid hormone receptor
superfamily Science 270, 1354-7.
www.nursa.org  NRS  | 2007 |  Vol. 5 |  DOI: 10.1621/nrs.05012 | Page 14 of 16
Review The mineralocorticoid receptorOuvrard-Pascaud, A., Sainte-Marie, Y., Benitah, J. P., Perrier, R.,
Soukaseum, C., Cat, A. N., Royer, A., Le Quang, K., Charpentier, F.,
Demolombe, S., Mechta-Grigoriou, F., Beggah, A.T., Maison-Blanche,
P., Oblin, M. E., Delcayre, C., Fishman, G. I., Farman, N., Escoubet, B.
and Jaisser, F. (2005) Conditional mineralocorticoid receptor expression
in the heart leads to life-threatening arrhythmias Circulation 111, 3025-33.
Pascual-Le Tallec, L., Demange, C. and Lombes, M. (2004) Human
mineralocorticoid receptor A and B protein forms produced by alternative
translation sites display different transcriptional activities Eur J Endocrinol
150, 585-90.
Pascual-Le Tallec, L., Kirsh, O., Lecomte, M. C., Viengchareun, S.,
Zennaro, M. C., Dejean, A. and Lombes, M. (2003) Protein inhibitor of
activated signal transducer and activator of transcription 1 interacts with
the N-terminal domain of mineralocorticoid receptor and represses its
transcriptional activity: implication of small ubiquitin-related modifier 1
modification Mol Endocrinol 17, 2529-42.
Pascual-Le Tallec, L., Simone, F., Viengchareun, S., Meduri, G., Thirman,
M. J. and Lombes, M. (2005b) The elongation factor ELL (eleven-nineteen
lysine-rich leukemia) is a selective coregulator for steroid receptor
functions Mol Endocrinol 19, 1158-69.
Pascual-Le Tallec, L. and Lombes, M. (2005a) The mineralocorticoid
receptor: a journey exploring its diversity and specificity of action Mol
Endocrinol 19, 2211-21.
Patel, P. D., Lopez, J. F., Lyons, D. M., Burke, S., Wallace, M. and
Schatzberg, A. F. (2000) Glucocorticoid and mineralocorticoid receptor
mRNA expression in squirrel monkey brain J Psychiatr Res 34, 383-92.
Patel, P. D., Sherman, T. G., Goldman, D. J. and Watson, S. J. (1989)
Molecular cloning of a mineralocorticoid (type I) receptor complementary
DNA from rat hippocampus Mol Endocrinol 3, 1877-85.
Pearce, P. and Funder, J.W. (1987) High affinity aldosterone binding
sites (type I receptors) in rat heart Clin Exp Pharmacol Physiol 14, 859-66.
Penfornis, P., Viengchareun, S., Le Menuet, D., Cluzeaud, F., Zennaro,
M. C. and Lombes, M. (2000) The mineralocorticoid receptor mediates
aldosterone-induced differentiation of T37i cells into brown adipocytes
Am J Physiol Endocrinol Metab 279, E386-94.
Pinon, G. M., Fagart, J., Souque, A., Auzou, G., Vandewalle, A. and
Rafestin-Oblin, M. E. (2004) Identification of steroid ligands able to
inactivate the mineralocorticoid receptor harboring the S810L mutation
responsible for a severe form of hypertension Mol Cell Endocrinol 217,
181-8.
Pitovski, D. Z., Drescher, M. J. and Drescher, D. G. (1993) High affinity
aldosterone binding sites (type I receptors) in the mammalian inner ear
Hear Res 69, 10-4.
Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B.,
Bittman, R., Hurley, S., Kleiman, J. and Gatlin, M. (2003) Eplerenone, a
selective aldosterone blocker, in patients with left ventricular dysfunction
after myocardial infarction N Engl J Med 348, 1309-21.
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A.,
Palensky, J. and Wittes, J. (1999) The effect of spironolactone on morbidity
and mortality in patients with severe heart failure. Randomized Aldactone
Evaluation Study Investigators N Engl J Med 341, 709-17.
Planey, S. L., Derfoul, A., Steplewski, A., Robertson, N. M. and Litwack,
G. (2002) Inhibition of glucocorticoid-induced apoptosis in 697 pre-B
lymphocytes by the mineralocorticoid receptor N-terminal domain J Biol
Chem 277, 42188-96.
Porter, T. E., Ghavam, S., Muchow, M., Bossis, I. and Ellestad, L. (2007)
Cloning of partial cDNAs for the chicken glucocorticoid and
mineralocorticoid receptors and characterization of mRNA levels in the
anterior pituitary gland during chick embryonic development Domest Anim
Endocrinol 33, 226-39.
Porter, G. A. and Edelman, I. S. (1964) The Action of Aldosterone and
Related Corticosteroids on Sodium Transport across the Toad Bladder
J Clin Invest 43, 611-20.
Pratt, W. B. and Toft, D. O. (1997) Steroid receptor interactions with heat
shock protein and immunophilin chaperones Endocr Rev 18, 306-60.
Pressley, L. and Funder, J.W. (1975) Glucocorticoid and mineralocorticoid
receptors in gut mucosa Endocrinology 97, 588-96.
Pryce, C. R., Feldon, J., Fuchs, E., Knuesel, I., Oertle, T., Sengstag, C.,
Spengler, M., Weber, E., Weston, A. and Jongen-Relo, A. (2005) Postnatal
ontogeny of hippocampal expression of the mineralocorticoid and
glucocorticoid receptors in the common marmoset monkey Eur J Neurosci
21, 1521-35.
Pujo, L., Fagart, J., Gary, F., Papadimitriou, D.T., Claes, A., Jeunemaitre,
X. and Zennaro, M. C. (2007) Mineralocorticoid receptor mutations are
the principal cause of renal type 1 pseudohypoaldosteronism Hum Mutat
28, 33-40.
Qin, W., Rudolph, A. E., Bond, B. R., Rocha, R., Blomme, E. A., Goellner,
J. J., Funder, J.W. and McMahon, E. G. (2003) Transgenic model of
aldosterone-driven cardiac hypertrophy and heart failure Circ Res 93,
69-76.
Quinkler, M., Meyer, B., Bumke-Vogt, C., Grossmann, C., Gruber, U.,
Oelkers, W., Diederich, S. and Bahr, V. (2002) Agonistic and antagonistic
properties of progesterone metabolites at the human mineralocorticoid
receptor Eur J Endocrinol 146, 789-99.
Quinkler, M., Zehnder, D., Eardley, K. S., Lepenies, J., Howie, A. J.,
Hughes, S.V., Cockwell, P., Hewison, M. and Stewart, P. M. (2005)
Increased expression of mineralocorticoid effector mechanisms in kidney
biopsies of patients with heavy proteinuria Circulation 112, 1435-43.
Quinkler, M., Meyer, B., Oelkers, W. and Diederich, S. (2003) Renal
inactivation, mineralocorticoid generation, and 11beta-hydroxysteroid
dehydrogenase inhibition ameliorate the antimineralocorticoid effect of
progesterone in vivo J Clin Endocrinol Metab 88, 3767-72.
Rafestin-Oblin, M. E., Couette, B., Radanyi, C., Lombes, M. and Baulieu,
E. E. (1989) Mineralocorticosteroid receptor of the chick intestine.
Oligomeric structure and transformation J Biol Chem 264, 9304-9.
Rafestin-Oblin, M. E., Souque, A., Bocchi, B., Pinon, G., Fagart, J. and
Vandewalle, A. (2003) The severe form of hypertension caused by the
activating S810L mutation in the mineralocorticoid receptor is cortisone
related Endocrinology 144, 528-33.
Robert-Nicoud, M., Flahaut, M., Elalouf, J. M., Nicod, M., Salinas, M.,
Bens, M., Doucet, A., Wincker, P., Artiguenave, F., Horisberger, J. D.,
Vandewalle, A., Rossier, B. C. and Firsov, D. (2001) Transcriptome of a
mouse kidney cortical collecting duct cell line: effects of aldosterone and
vasopressin Proc Natl Acad Sci U S A 98, 2712-6.
Rogerson, F. M., Yao, Y. Z., Elsass, R. E., Dimopoulos, N., Smith, B. J.
and Fuller, P. J. (2007) A critical region in the mineralocorticoid receptor
for aldosterone binding and activation by cortisol: evidence for a common
mechanism governing ligand binding specificity in steroid hormone
receptors Mol Endocrinol 21, 817-28.
Rondinone, C. M., Rodbard, D. and Baker, M. E. (1993) Aldosterone
stimulated differentiation of mouse 3T3-L1 cells into adipocytes
Endocrinology 132, 2421-6.
Ronzaud, C., Loffing, J., Bleich, M., Gretz, N., Grone, H. J., Schutz, G.
and Berger, S. (2007) Impairment of sodium balance in mice deficient in
renal principal cell mineralocorticoid receptor J Am Soc Nephrol 18,
1679-87.
Rosenfeld, M. G., Lunyak, V.V. and Glass, C. K. (2006) Sensors and
signals: a coactivator/corepressor/epigenetic code for integrating
signal-dependent programs of transcriptional response Genes Dev 20,
1405-28.
Rossier, B. C., Pradervand, S., Schild, L. and Hummler, E. (2002)
Epithelial sodium channel and the control of sodium balance: interaction
between genetic and environmental factors Annu Rev Physiol 64, 877-97.
Rozeboom, A. M., Akil, H. and Seasholtz, A. F. (2007) Mineralocorticoid
receptor overexpression in forebrain decreases anxiety-like behavior and
alters the stress response in mice Proc Natl Acad Sci U S A 104, 4688-93.
www.nursa.org  NRS  | 2007 |  Vol. 5 |  DOI: 10.1621/nrs.05012 | Page 15 of 16
Review The mineralocorticoid receptorSainte Marie, Y., Toulon, A., Paus, R., Maubec, E., Cherfa, A., Grossin,
M., Descamps, V., Clemessy, M., Gasc, J. M., Peuchmaur, M., Glick, A.,
Farman, N. and Jaisser, F. (2007) Targeted skin overexpression of the
mineralocorticoid receptor in mice causes epidermal atrophy, premature
skin barrier formation, eye abnormalities, and alopecia Am J Pathol 171,
846-60.
Savory, J. G., Prefontaine, G. G., Lamprecht, C., Liao, M., Walther, R.
F., Lefebvre, Y. A. and Hache, R. J. (2001) Glucocorticoid receptor
homodimers and glucocorticoid-mineralocorticoid receptor heterodimers
form in the cytoplasm through alternative dimerization interfaces Mol Cell
Biol 21, 781-93.
Schwartz, B. and Wysocki, A. (1997) Mineralocorticoid receptors in the
rabbit iris-ciliary body Ophthalmic Res 29, 42-7.
Seeler, J. S. and Dejean, A. (2003) Nuclear and unclear functions of
SUMO Nat Rev Mol Cell Biol 4, 690-9.
Shibata, S., Nagase, M., Yoshida, S., Kawachi, H. and Fujita, T. (2007)
Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1
Hypertension 49, 355-64.
So, A.Y., Chaivorapol, C., Bolton, E. C., Li, H. and Yamamoto, K. R.
(2007) Determinants of cell- and gene-specific transcriptional regulation
by the glucocorticoid receptor PLoS Genet 3, e94.
Soundararajan, R., Zhang, T.T., Wang, J., Vandewalle, A. and Pearce,
D. (2005) A novel role for glucocorticoid-induced leucine zipper protein
in epithelial sodium channel-mediated sodium transport J Biol Chem 280,
39970-81.
Stockand, J. D. and Meszaros, J. G. (2003) Aldosterone stimulates
proliferation of cardiac fibroblasts by activating Ki-RasA and MAPK1/2
signaling Am J Physiol Heart Circ Physiol 284, H176-84.
Sturm, A., Bury, N., Dengreville, L., Fagart, J., Flouriot, G., Rafestin-Oblin,
M. E. and Prunet, P. (2005) 11-deoxycorticosterone is a potent agonist
of the rainbow trout (Oncorhynchus mykiss) mineralocorticoid receptor
Endocrinology 146, 47-55.
Sugiyama, T., Yoshimoto, T., Hirono, Y., Suzuki, N., Sakurada, M.,
Tsuchiya, K., Minami, I., Iwashima, F., Sakai, H., Tateno, T., Sato, R. and
Hirata, Y. (2005a) Aldosterone increases osteopontin gene expression
in rat endothelial cells Biochem Biophys Res Commun 336, 163-7.
Sugiyama, T., Yoshimoto, T., Tsuchiya, K., Gochou, N., Hirono, Y., Tateno,
T., Fukai, N., Shichiri, M. and Hirata, Y. (2005b) Aldosterone induces
angiotensin converting enzyme gene expression via a JAK2-dependent
pathway in rat endothelial cells Endocrinology 146, 3900-6.
Takeda, A. N., Pinon, G. M., Bens, M., Fagart, J., Rafestin-Oblin, M. E.
and Vandewalle, A. (2007) The synthetic androgen methyltrienolone
(r1881) acts as a potent antagonist of the mineralocorticoid receptor Mol
Pharmacol 71, 473-82.
Teixeira, M., Viengchareun, S., Butlen, D., Ferreira, C., Cluzeaud, F.,
Blot-Chabaud, M., Lombes, M. and Ferrary, E. (2006) Functional
IsK/KvLQT1 potassium channel in a new corticosteroid-sensitive cell line
derived from the inner ear J Biol Chem 281, 10496-507.
Tirard, M., Almeida, O. F., Hutzler, P., Melchior, F. and Michaelidis, T. M.
(2007) Sumoylation and proteasomal activity determine the transactivation
properties of the mineralocorticoid receptor Mol Cell Endocrinol 268, 20-9.
Van Eekelen, J. A., Jiang, W., De Kloet, E. R. and Bohn, M. C. (1988)
Distribution of the mineralocorticoid and the glucocorticoid receptor
mRNAs in the rat hippocampus J Neurosci Res 21, 88-94.
Viengchareun, S., Penfornis, P., Zennaro, M. C. and Lombes, M. (2001)
Mineralocorticoid and glucocorticoid receptors inhibit UCP expression
and function in brown adipocytes Am J Physiol Endocrinol Metab 280,
E640-9.
Wald, H., Goldstein, O., Asher, C., Yagil, Y. and Garty, H. (1996)
Aldosterone induction and epithelial distribution of CHIF Am J Physiol
271, F322-9.
Walther, R. F., Atlas, E., Carrigan, A., Rouleau, Y., Edgecombe, A.,
Visentin, L., Lamprecht, C., Addicks, G. C., Hache, R. J. and Lefebvre,
Y. A. (2005) A serine/threonine-rich motif is one of three nuclear
localization signals that determine unidirectional transport of the
mineralocorticoid receptor to the nucleus J Biol Chem 280, 17549-61.
Wang, X., Skelley, L., Cade, R. and Sun, Z. (2006) AAV delivery of
mineralocorticoid receptor shRNA prevents progression of cold-induced
hypertension and attenuates renal damage Gene Ther 13, 1097-103.
Wielputz, M. O., Lee, I. H., Dinudom, A., Boulkroun, S., Farman, N., Cook,
D. I., Korbmacher, C. and Rauh, R. (2007) (NDRG2) stimulates
amiloride-sensitive Na+ currents in Xenopus laevis oocytes and fisher rat
thyroid cells J Biol Chem 282, 28264-73.
Wong, S., Brennan, F. E., Young, M. J., Fuller, P. J. and Cole, T. J. (2007)
A direct effect of aldosterone on endothelin-1 gene expression in vivo
Endocrinology 148, 1511-7.
Xu, B. E., Stippec, S., Lazrak, A., Huang, C. L. and Cobb, M. H. (2005b)
WNK1 activates SGK1 by a phosphatidylinositol 3-kinase-dependent and
non-catalytic mechanism J Biol Chem 280, 34218-23.
Xu, B. E., Stippec, S., Chu, P.Y., Lazrak, A., Li, X. J., Lee, B. H., English,
J. M., Ortega, B., Huang, C. L. and Cobb, M. H. (2005a) WNK1 activates
SGK1 to regulate the epithelial sodium channel Proc Natl Acad Sci U S
A 102, 10315-20.
Yokota, K., Shibata, H., Kurihara, I., Kobayashi, S., Suda, N.,
Murai-Takeda, A., Saito, I., Kitagawa, H., Kato, S., Saruta, T. and Itoh,
H. (2007) Coactivation of the N-terminal transactivation of
mineralocorticoid receptor by Ubc9 J Biol Chem 282, 1998-2010.
Yoshida, M., Ma, J., Tomita, T., Morikawa, N., Tanaka, N., Masamura,
K., Kawai, Y. and Miyamori, I. (2005) Mineralocorticoid receptor is
overexpressed in cardiomyocytes of patients with congestive heart failure
Congest Heart Fail 11, 12-6.
Young, M., Fullerton, M., Dilley, R. and Funder, J. (1994)
Mineralocorticoids, hypertension, and cardiac fibrosis J Clin Invest 93,
2578-83.
Yuan, J., Jia, R. and Bao, Y. (2007) Aldosterone up-regulates production
of plasminogen activator inhibitor-1 by renal mesangial cells J Biochem
Mol Biol 40, 180-8.
Zennaro, M. C., Le Menuet, D. and Lombes, M. (1996) Characterization
of the human mineralocorticoid receptor gene 5'-regulatory region:
evidence for differential hormonal regulation of two alternative promoters
via nonclassical mechanisms Mol Endocrinol 10, 1549-60.
Zennaro, M. C., Le Menuet, D., Viengchareun, S., Walker, F., Ricquier,
D. and Lombes, M. (1998) Hibernoma development in transgenic mice
identifies brown adipose tissue as a novel target of aldosterone action J
Clin Invest 101, 1254-60.
Zennaro, M. C., Keightley, M. C., Kotelevtsev, Y., Conway, G. S., Soubrier,
F. and Fuller, P. J. (1995) Human mineralocorticoid receptor genomic
structure and identification of expressed isoforms J Biol Chem 270,
21016-20.
www.nursa.org  NRS  | 2007 |  Vol. 5 |  DOI: 10.1621/nrs.05012 | Page 16 of 16
Review The mineralocorticoid receptor